MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
Tina Gruosso(Inserm), Fatima Mechta‐Grigoriou(Inserm)
Cited by 55
Related Papers
Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms
|Nature Communications|2020|374
Oxidative stress promotes myofibroblast differentiation and tumour spreading
|EMBO Molecular Medicine|2010|333
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression
|Nature Materials|2020|307
PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
|Cell Metabolism|2018|297
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
|Nature Communications|2018|276